Maximizing the potential of precision medicine for patients and healthcare services is a major societal challenge. It requires a holistic approach to the development of therapeutic strategies and a re-thinking of the entire process, including the role of the respective stakeholders and the way they interact, from the early steps of drug development to access in real life.

Read more info here

Structural elements of European biomedical research funding should be developed with a priority over funding of individual thematic areas and topics.

More info here

The European Council for Health Research will provide a science-led vision and long-term strategy for health research, which involves citizens, patients, health professionals and researchers

More info here

*The Scientific Panel for Health (SPH) is a science-led expert group based on the provisions of the Horizon 2020 Specific Programme that has been tasked with helping to achieve better health and wellbeing for all.

More info here

The BioMed Alliance agrees with the European Commission that efforts now need to be more strongly directed towards ensuring the Directive’s proper implementation and enforcement in all EU Member States.

More info here

BioMed Alliance and FEAM have joined forces to highlight the need to provide a more robust environment for academic clinical and health research in Europe in view of the forthcoming EU Framework Programme for Research and Innovation (FP9).

More info here

To provide more robust feedback on Horizon 2020 and help shape the future of European research and innovation, the Alliance for Biomedical Research in Europe (BioMed Alliance) surveyed its membership.

More info here:

BioMed Alliance recommendations for the future of EU research and innovation

H2020's opportunities and challenges

BioMed Alliance response to the European Medicines Agency’s public consultation: Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products

The European Medicines Agency has released for public consultation a draft guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. 

More info here

European researchers call for the intensification of efforts to develop and adopt alternative approaches, while ensuring a viable context for the pursuit of animal experimentation, when unavoidable.

More info here

More info here:

BioMed Alliance statement on the Scientific Panel for Health Paper Vision

The Scientific Health Papaer Vision

More info here

More info here.

More info here

Statement by the Alliance for Biomedical Research in Europe.

More info here

Statement by the Alliance for Biomedical Research in Europe.

More info here.

Statement by the Alliance for Biomedical Research on EU Data Protection Regulation (March 2015)

More info here

The Alliance for Biomedical Research in Europe endorses the League of European Research Universities’ position and the Wellcome Trust’s Statement in support of the EU Directive on the protection of animals used for scientific purposes.

More info here:

Statement by the Alliance for Biomedical Research in Europe on the European Commission’s proposal for a European Data Protection Regulation (February 2013)

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.